The adverse events of the 2 groups of patients mainly manifested as hematology and gastrointestinal toxicity, events similar to those described previously.7,20 There were significantly more grade 3-4 adverse events in the novel anti-HER2 ADCs group than in the HP combined with chemotherapy group, even exceeding the values reported in the DESTINY-Breast03 study.7 These results may be due to the combined effect of many factors, including drug load, tumor load, previous medication, and number of lines of treatment. The gene discussed is ERBB2; the disease is neoplasm.